2200 BRIDGE PKWY SUITE #102, REDWOOD CITY, CA
Christian Nolet Resigns from Jasper Therapeutics Board; Svetlana Lucas Appointed
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Financial Results, Press Release
BEACON & OLE Data Update January 8, 2026
Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth
ETESIAN Data + BEACON Investigation Update December 2025
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants
Q1
FY 2025
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
S-8 POS